GBT

Oncology

The systems needed to deliver GBT testing consistently across the NHS are still evolving to keep pace with these scientific advances.

News

In its third big licensing deal of the week, Eli Lilly has tapped RNA-editing specialist Ascidian for kidney disease therapies in a $1.9bn alliance.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.